NCT03078075View on ClinicalTrials.gov

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

403

Participants

Timeline

Start Date

May 5, 2017

Primary Completion Date

July 3, 2019

Study Completion Date

July 25, 2019

Conditions
Methamphetamine Use Disorder
Interventions
DRUG

Naltrexone: Vivitrol®

Naltrexone: 380 mg vial, 4 intramuscular injections administered every 3 weeks

DRUG

Placebo (PLB) Injectable

Placebo: 4 intramuscular injections administered every 3 weeks

DRUG

Bupropion: Wellbutrin XL®

Bupropion: 450 mg oral dose daily

DRUG

Placebo (PLB) Oral

Placebo: once-daily oral placebo tablets

Trial Locations (8)

10032

New York State Psychiatric Institute (NYSPI)- Substance Use Research Center (SURC), New York

29671

Behavioral Health Services (BHS) of Pickens County, Pickens

55415

Hennepin County Medical Center- Berman Center for Research, Minneapolis

75235

University of Texas Southwestern Medical Center, Dallas

77054

University of Texas Health Science Center - Center for Neurobehavioral Research on Addiction (CNRA), Houston

90038

University of California Los Angeles (UCLA) Center for Behavioral Addiction Medicine (CBAM), Los Angeles

94102

Substance Use Research Unit (SURU) at the San Francisco Dept. of Public Health, San Francisco

97214

CODA, Inc., Portland

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

The Emmes Company, LLC

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER

NCT03078075 - Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder | Biotech Hunter | Biotech Hunter